Calliditas plans to file rare kidney disease drug Nefecon after phase 3 successSwedish biotech Calliditas has announced plans to file its rare disease drug Nefecon with the FDA early next Share XCalliditas plans to file rare kidney disease drug Nefecon after phase 3 successhttps://pharmaphorum.com/news/calliditas-plans-to-file-rare-disease-drug-nefecon-after-phase-3-success/
